Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yemen uncomplicated falciparum malaria efficacy study of artesunate + sulfadoxine/pyrimethamine and artemether-lumefantrine
ACTRN12610000696099Phase 4Completed
- Sponsor
- Haiti Ministry of Public Health and Population
- Start
- Nov 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of artesunate, sulfadoxine, pyrimethamine, artemether and lumefantrine in malaria and Falciparum malaria (PF) (2 arms), sponsored by Haiti Ministry of Public Health and Population. Primary endpoints: Artesunate + sulfadoxine/pyrimethamine treatment failure rate, Artemether-lumefantrine treatment failure rate and 1 more. Started Nov 2009; status: completed.
02
Drugs
artesunatesulfadoxinepyrimethamineartemetherlumefantrine
03
Conditions
malariaFalciparum malaria (PF)
Beyond the preview
Go deeper on ACTRN12610000696099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000696099.